Wells Fargo Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $50

Wells Fargo analyst Larry Biegelsen maintains $Tandem Diabetes Care(TNDM.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 58.

Futu NewsJun 28 21:31 · Ratings

Is weight loss medicine or stock market bomb? Eli Lilly and Co's new drug tirzepatide caused a sharp drop in sleep device stocks.

The recent clinical trial results of the new weight loss drug tirzepatide have not only caused a sensation in the medical community, but also stirred up waves in the stock market.

Zhitong FinanceJun 25 07:50

Tandem Diabetes, DexCom See Weakness Following ADA Conference

Seeking AlphaJun 25 00:06

Lake Street Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $75

Lake Street analyst Brooks O'Neil maintains $Tandem Diabetes Care(TNDM.US)$ with a buy rating, and maintains the target price at $75.According to TipRanks data, the analyst has a success rate of 43.9%

Futu NewsJun 24 21:31 · Ratings

TD Cowen Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $45

TD Cowen analyst Josh Jennings maintains $Tandem Diabetes Care(TNDM.US)$ with a buy rating, and maintains the target price at $45.According to TipRanks data, the analyst has a success rate of 51.0% an

Futu NewsJun 24 19:31 · Ratings

Tandem Mobi Improves Quality of Life for People Living With Type 1 Diabetes in New Data Shared at American Diabetes Association Scientific Sessions

PDF Version SAN DIEGO--(BUSINESS WIRE)--Jun. 22, 2024-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today presented new real-world insight

Tandem Diabetes Care Jun 22 12:00